# Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Canonical URL: https://biopharmsignal.com/news/TBPH/theravance-biopharma-inc-reports-third-quarter-2025-financial-results-and-provides-corporate-update
Ticker: TBPH
Company: Theravance Biopharma
Source: Theravance Biopharma
Published: 2025-11-10 21:05 EST
Original Source URL: https://investor.theravance.com
## Summary

YUPELRI ® net sales reached an all-time high of $71.4 million , recognized by Viatris, up 15% year-over-year     1     , and achieved record brand profitability Open-label portion of the pivotal Phase 3 CYPRESS study of ampreloxetine now complete; topline readout on track for Q1 2026 Company to

## Article Body
YUPELRI ® net sales reached an all-time high of $71.4 million , recognized by Viatris, up 15% year-over-year     1     , and achieved record brand profitability Open-label portion of the pivotal Phase 3 CYPRESS study of ampreloxetine now complete; topline readout on track for Q1 2026 Company to
## Recent Company News
- 2026-05-07 12:30 EST — [Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TBPH/theravance-biopharma-inc-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Theravance Biopharma
- 2026-03-19 12:30 EST — [Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TBPH/theravance-biopharma-inc-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update) — Source: Theravance Biopharma
- 2026-03-03 13:30 EST — [Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions](https://biopharmsignal.com/news/TBPH/theravance-biopharma-reports-phase-3-cypress-study-did-not-meet-primary-endpoint-board-accelerates-strategic-review-and-announces-cost-reduction-actions) — Source: Theravance Biopharma
- 2025-11-20 16:00 EST — [Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025](https://biopharmsignal.com/news/TBPH/theravance-biopharma-to-host-virtual-kol-investor-event-to-review-ampreloxetine-phase-3-clinical-development-program-ahead-of-topline-data-in-q1-2026-on-december-8-2025) — Source: Theravance Biopharma
- 2025-11-19 11:00 EST — [Theravance Biopharma to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/TBPH/theravance-biopharma-to-participate-in-upcoming-investor-conferences) — Source: Theravance Biopharma
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)